4142:TPE
Adimmune Corp
NT$15.85
arrow_downward
-1.86%(-0.30) 1D
ඉල් 19, 13:30:08 ග්රිමවේ+8 · TWD
search
සියලු සංකේත
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_auto4142 සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
NT$16.20
ඉහළ
NT$16.25
පහළ
NT$15.70
වෙ.පො ප්රාග්ධනය
බි6.81
දළ පරිමාව
මි1.09
හඬ පරිමාණය
මි1.60
P/E අනුපාතය
91.85
සති-52 ඉහළ
NT$21.50
සති-52 පහළ
NT$15.65
EPS
NT$0.17
ගෙවිය යුතු කොටස්
මි235.29
සේවකයින් ගණන
564
විවෘත කරන්න
NT$16.20
ඉහළ
NT$16.25
පහළ
NT$15.70
වෙ.පො ප්රාග්ධනය
බි6.81
දළ පරිමාව
මි1.09
හඬ පරිමාණය
මි1.60
P/E අනුපාතය
91.85
සති-52 ඉහළ
NT$21.50
සති-52 පහළ
NT$15.65
EPS
NT$0.17
ගෙවිය යුතු කොටස්
මි235.29
සේවකයින් ගණන
564
පුවත් සහ කථා
වෙබ් මූලාශ්ර සහ ප්රවෘත්ති හවුල්කරුවන්ගෙන්
Yahoo Finance
·
මිනිත්තු 32කට පෙර
S&P 500, Nasdaq, Dow End Lower As Anthropic Trading Debut Fails To Provide Adequate Confidence — ANT, META, AAPL, GME In Focus
The Motley Fool
·
පැය 13කට පෙර
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
The Harvard Law School Forum on Corporate Governance
·
පැය 10කට පෙර
Board Practices and Composition in the Russell 3000 and S&P 500
Barron's
·
පැය 11කට පෙර
S&P 500 Futures Rise in Premarket Trading; Credicorp, Intercorp Finl Svcs Lead
පැතිකඩ
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp ගැන